An observational study in Graves Disease and Graves Ophthalmopathy, sponsored by Elazıg Fethi Sekin Sehir Hastanesi. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Elazıg Fethi Sekin Sehir Hastanesi · Observational
This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.
150 studies on the registry are indexed under Graves Disease; 53 are open to participants now.
This study's planned enrollment of 100 is close to the median of 110 across 57 observational studies indexed under Graves Disease.
Browse Graves Disease studies →Elazıg Fethi Sekin Sehir Hastanesi is the lead sponsor of 29 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of adult patients diagnosed with Graves' disease who are followed in the endocrinology and ophthalmology clinics of the participating institution. Patients who meet the inclusion criteria and have available optical coherence tomography (OCT) measurements and laboratory data will be included in the patient group.
The control group will consist of age- and sex-matched healthy volunteers without a history of thyroid disease or ocular pathology, recruited from individuals undergoing routine ophthalmologic examination.
All participants will be evaluated for neuroretinal structural parameters using OCT and systemic inflammatory markers obtained from laboratory tests.
Diagnosis of Graves' disease (for the patient group)
No known thyroid disease in healthy control participants
Availability of optical coherence tomography (OCT) measurements and laboratory data
Time interval between OCT examination and blood sampling ≤ 10 days
Exclusion Criteria:
Macular diseases, uveitis, or severe refractive error (high myopia >6 diopters)
Diabetic retinopathy
History of previous intraocular surgery
History of active infection, malignancy, or systemic inflammatory disease
Poor-quality OCT measurements (segmentation errors or low signal strength)
Age-matched healthy individuals without known thyroid disease or autoimmune disorders who underwent ophthalmologic examination and optical coherence tomography evaluation.
Patients diagnosed with Graves disease who do not have clinical signs of Graves ophthalmopathy and who underwent optical coherence tomography evaluation.
Patients diagnosed with Graves disease who have clinical findings consistent with Graves ophthalmopathy and who underwent optical coherence tomography evaluation.
Peripapillary Retinal Nerve Fiber Layer Thickness
Evaluation and comparison of peripapillary retinal nerve fiber layer thickness values in different quadrants among study groups.
Time frame: Retrospective evaluation of OCT measurements obtained between August 2018 and January 2026
Macular Thickness Measured by Optical Coherence Tomography
Comparison of macular thickness measurements among healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy.
Time frame: Retrospective evaluation of OCT measurements obtained between August 2018 and January 2026
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Elazıg Fethi Sekin Sehir Hastanesi